Edition:
United States

Profile: Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

11.15EUR
26 May 2017
Change (% chg)

€0.05 (+0.45%)
Prev Close
€11.10
Open
€11.05
Day's High
€11.15
Day's Low
€10.97
Volume
34,013
Avg. Vol
145,207
52-wk High
€14.69
52-wk Low
€8.21

Ablynx NV is a Belgium-based biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx NV has more than 30 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co, Inc., Merck Serono and Novartis.

Company Address

Ablynx NV

Technologiepark-Zwijnaarde 21
GENT     9052
P: +329.2620000
F: +329.2620001

Company Web Links